Growth-hormone-axis research
CJC-1295
Early human researchCJC-1295 is a peptide designed to stimulate the pituitary’s growth-hormone pathway. The studied long-acting DAC form differs from products sometimes called “CJC without DAC.” A rise in a hormone is not proof of healthier aging.
Source review: September 9, 2026. Scientific evidence and trial records change over time.
01 · What is it?
The identity comes first.
CJC-1295 is a peptide designed to stimulate the pituitary’s growth-hormone pathway. The studied long-acting DAC form differs from products sometimes called “CJC without DAC.” A rise in a hormone is not proof of healthier aging.
Scientific classification: Synthetic growth-hormone-releasing-hormone analogue
For example. It sends a message to the hormone-release department rather than supplying growth hormone directly.
02 · How does it work?
The signal, explained.
It activates a pituitary receiving station that prompts growth-hormone release. The released hormone can then prompt other tissues, including the liver, to change their signaling.
The key research focus is Growth-hormone-releasing hormone receptor (GHRHR). A target describes where an interaction may occur; it does not by itself establish a benefit.
Learn the Science · mechanism
GHRHR agonism in pituitary somatotrophs increases cAMP signaling and growth-hormone secretion. The DAC modification enables albumin binding and prolonged exposure in the studied molecule.
03 · What happens after the signal?
Follow the downstream effects.
Released growth hormone can stimulate hepatic IGF-1 production via growth-hormone receptor/JAK2/STAT signaling. IGF-1 changes are biomarkers and do not establish improved strength or recovery.
To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.
04 · What is it commonly researched for?
The questions researchers are asking.
Researchers have examined GH secretion, IGF-1 and endocrine pharmacology.
These are areas of investigation, not promises about a Maison product.
05 · Body systems involved
Where the biology connects.
- Pituitary
- Releases hormones in response to hypothalamic and receptor signals.
- Liver
- A central site of nutrient handling, metabolic enzymes and selected downstream hormone responses.
06 · Receptor / target profile
The molecular reference card.
- Primary receptor or target
- Growth-hormone-releasing hormone receptor (GHRHR)
- Secondary interactions
- No additional primary target established for the research claim discussed.
- Where it is found
- GHRHR on anterior pituitary somatotroph cells.
- Activation, inhibition or interaction
- GHRHR agonism in pituitary somatotrophs increases cAMP signaling and growth-hormone secretion. The DAC modification enables albumin binding and prolonged exposure in the studied molecule.
- Important downstream pathways
- Released growth hormone can stimulate hepatic IGF-1 production via growth-hormone receptor/JAK2/STAT signaling. IGF-1 changes are biomarkers and do not establish improved strength or recovery.
07 · Evidence quality
What carries weight—and what does not.
STRONGER EVIDENCE
Convincing replicated human evidence for the broad wellness claims is not established.
EMERGING HUMAN EVIDENCE
Small studies in healthy adults demonstrated GH/IGF-1 responses. They do not establish long-term wellness benefit.
EARLY / PRECLINICAL EVIDENCE
The mechanistic observations described above do not establish the same outcomes in people.
UNKNOWN OR NOT WELL ESTABLISHED
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.
08 · Who is studying it?
Follow the original research.
No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.
Regulatory context: No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
VIEW CURRENT CLINICAL TRIALSRegistry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.
09 · Research terminology
A small glossary for this page.
Target
The molecule or biological structure a compound interacts with.
Pathway
A sequence of cellular events connecting a signal to a response.
Preclinical
Research outside human clinical trials, including cells and animals.
cAMP
Cyclic adenosine monophosphate: a small intracellular messenger used by many receptors.
IGF-1
Insulin-like growth factor 1: a hormone influenced by growth hormone, with growth and metabolic signaling roles.
JAK2
An intracellular enzyme that relays signals from receptors including the growth-hormone receptor.
STAT
A family of proteins that can relay receptor signals to changes in gene expression.
somatotroph
A pituitary cell that produces growth hormone.
DAC
Drug affinity complex: a modification used in the studied long-acting CJC-1295 molecule to enable albumin binding.
albumin
An abundant blood protein that can carry molecules and change how long they remain in circulation.
actin
A protein forming part of the cell’s internal structural and movement machinery.
endocrine
Relating to hormone signaling between tissues.
Biomarker
A measurable biological feature. A change in a marker does not always translate into a meaningful health outcome.
Target engagement
Evidence that a compound actually reaches and interacts with the intended biological target.
Randomized controlled trial
A study that assigns participants by chance to comparison groups, helping separate an intervention’s effects from other influences.
10 · Research status & limitations
Keep the boundaries visible.
No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
The main evidence category here is early human research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.
11 · References / continue reading
Go to the source.
Individual study links support the associated research discussion. Literature-search links are clearly labelled and help you explore further; they are not themselves proof of a claim. Sponsor announcements should be read alongside published papers and current regulatory records.